JW to conduct Phase I trial for new anticancer medicine

JW Pharmaceutical has recently announced that it will conduct Phase I clinical trial for CWP231A, a candidate anticancer medicine that interrupts biochemical signals to eradicate leukemia stem cells without affecting normal cells, in the United States within this month.

Last month, the company obtained the approval of clinical tests by the U.S. Food and Drug Administration to develop the dru...